Long-term treatment with infliximab in patients with sarcoidosis

Respiration

Volumn 83, Issue 3, 2012, Pages 218-224

  Hostettler, Katrin E ^a   Studler, Ueli ^a   Tamm, Michael ^a   Brutsche, Martin H ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

Corticosteroids; Infliximab; Sarcoidosis; Tumour necrosis factor

Indexed keywords

AZATHIOPRINE; INFLIXIMAB; PREDNISONE;

ADULT; AGED; ARTICLE; BRADYCARDIA; CHRONIC STEROID RESISTANT LUNG SARCOIDOSIS; CLINICAL ARTICLE; CLINICAL ASSESSMENT; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; FORCED VITAL CAPACITY; GRANULOMA; HUMAN; LUNG FUNCTION TEST; LUNG SARCOIDOSIS; MALE; MEDICAL RECORD REVIEW; MYOCARDIAL GRANULOMA; PRIORITY JOURNAL; REMISSION; RETROSPECTIVE STUDY; SARCOIDOSIS; TREATMENT DURATION; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

ADULT; AGED; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; FEMALE; HUMANS; MALE; MIDDLE AGED; RESPIRATORY FUNCTION TESTS; RETROSPECTIVE STUDIES; SARCOIDOSIS;

EID: 84857370733     PISSN: 00257931     EISSN: 14230356     Source Type: Journal    
DOI: 10.1159/000328738     Document Type: Article

References (37)

1. Baughman RP, Drent M, Kavuru M, et al: Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement. Am J Respir Crit Care Med 2006; 174: 795-802. (Pubitemid 44511661)
2. Newman LS, Rose CS, Maier LA: Sarcoidosis. N Engl J Med 1997; 336: 1224-1234. (Pubitemid 27183653)
3. Iannuzzi MC, Rybicki BA, Teirstein AS: Sarcoidosis. N Engl J Med 2007; 357: 2153-2165.
4. Rybicki BA, Iannuzzi MC: Epidemiology of sarcoidosis: recent advances and future prospects. Semin Respir Crit Care Med 2007; 28: 22-35. (Pubitemid 46371213)
5. Lower EE, Weiss KL: Neurosarcoidosis. Clin Chest Med 2008; 29: 475-492. (Pubitemid 351778217)
6. Judson MA: Sarcoidosis: clinical presentation, diagnosis, and approach to treatment. Am J Med Sci 2008; 335: 26-33.
7. Rybicki BA, Iannuzzi MC, Frederick MM, et al: Familial aggregation of sarcoidosis. A case-control etiologic study of sarcoidosis (ACCESS). Am J Respir Crit Care Med 2001; 164: 768-780.
8. Müller-Quernheim J, Schürmann M, Hofmann S, et al: Genetics of sarcoidosis. Clin Chest Med 2008; 29: 391-414. (Pubitemid 351778209)
9. Sverrild A, Backer V, Kyvik KO, et al: Heredity in sarcoidosis - a registry-based twin study. Thorax 2008; 63: 894-896.
10. Steele MP, Brown KK: Genetic predisposition to respiratory diseases: infiltrative lung diseases. Respiration 2007; 74: 601-608. (Pubitemid 350164503)
11. Baughman RP, Iannuzzi M: Tumour necrosis factor in sarcoidosis and its potential for targeted therapy. BioDrugs 2003; 17: 425-431. (Pubitemid 37500758)
12. Baughman RP, Costabel U, du Bois RM: Treatment of sarcoidosis. Clin Chest Med 2008; 29: 533-548. (Pubitemid 351784486)
13. Martin WJ, Iannuzzi MC, Gail DB, et al: Future directions in sarcoidosis research: summary of an NHLBI working group. Am J Respir Crit Care Med 2004; 170: 567-571. (Pubitemid 39209141)
14. Lower EE, Baughman RP: Prolonged use of methotrexate for sarcoidosis. Arch Intern Med 1995; 155: 846-851.
15. Steffen M, Pettersen J, Oldigs M, et al: Increased secretion of tumour necrosis factor alpha, interleukin-1-beta, and interleukin-6 by alveolar macrophages from patients with sarcoidosis. J Allergy Clin Immunol 1993; 91: 939-949. (Pubitemid 23118511)
16. Ziegenhagen MW, Benner UK, Zissel G, et al: Sarcoidosis: TNF-α release from alveolar macrophages and serum level of sIL-2R are prognostic markers. Am J Respir Crit Care Med 1997; 156: 1586-1592. (Pubitemid 27505529)
17. Ziegenhagen MW, Rothe ME, Zissel G, et al: Exaggerated TNF-α release of alveolar macrophages in corticosteroid-resistant sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2002; 19: 185-190.
18. Baughman RP, Strohofer SA, Buchsbaum J, et al: Release of tumour necrosis factor by alveolar macrophages of patients with sarcoidosis. J Lab Clin Med 1990; 115: 36-42. (Pubitemid 20044133)
19. Baughman RP, Lower EE: Infliximab for refractory sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2001; 18: 70-74. (Pubitemid 32280539)
20. Yee AMF, Pochapin MB: Treatment of complicated sarcoidosis with infliximab anti-tumour necrosis factor-α therapy. Ann Intern Med 2001; 135: 27-31. (Pubitemid 32619280)
21. Roberts SD, Wilkes DS, Burgett RA, et al: Refractory sarcoidosis responding to infliximab. Chest 2003; 124: 2028-2031. (Pubitemid 37433610)
22. Baughman RP, Judson MA, Costabel U, et al: Randomized, double-blind, placebo-controlled trial of infliximab in patients with chronic pulmonary sarcoidosis. Chest 2005; 128: 202S.
23. Doty JD, Mazur JE, Judson MA: Treatment of sarcoidosis with infliximab. Chest 2005; 127: 1064-1071. (Pubitemid 40775543)
24. Pettersen JA, Zochodne DW, Bell RB, et al: Refractory neurosarcoidosis responding to infliximab. Neurology 2002; 59: 1660-1661. (Pubitemid 35387087)
25. Pritchard C, Nadarajah K: Tumour necrosis factor α inhibitor treatment for sarcoidosis refractory to conventional treatments: a report of five patients. Ann Rheum Dis 2004; 63: 318-320. (Pubitemid 38250677)
26. Saleh S, Ghodsian S, Yakimova V, Henderson J, Sharma OP: Effectiveness of infliximab in treating selected patients with sarcoidosis. Respir Med 2006; 100: 2053-2059. (Pubitemid 44514944)
27. Elfferich MD, Nelemans P, Ponds R, et al: Everyday cognitive failure in sarcoidosis: the prevalence and the effect of anti-TNF-α treatment. Respiration 2010; 80: 212-219.
28. Rossman MD, Newman LS, Baughman RP, et al: A double-blind, placebo-controlled trial of infliximab in subjects with active pulmonary sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2006; 23: 201-208. (Pubitemid 47596315)
29. Judson MA, Baughman RP, Costabel U, et al: Efficacy of infliximab in extrapulmonary sarcoidosis: results from a randomized trial. Eur Respir J 2008; 31: 1189-1196.
30. Judson MA, Baughman RP, Teirstein AS, et al: Defining organ involvement in sarcoidosis: the ACCES proposed instrument. Sarcoidosis Vasc Diffuse Lung Dis 1999; 16: 75-86. (Pubitemid 29164274)
31. Wasfi YS, Rose CS, Murphy JR, et al: A new tool to assess sarcoidosis severity. Chest 2006; 129: 1234-1245.
32. Santos E, Shaunak S, Renowden S, et al: Treatment of refractory neurosarcoidosis with infliximab. J Neurol Neurosurg Psychiatry 2010; 81: 241-246.
33. Stagaki E, Mountford W, Lackland D, et al: The treatment of lupus pernio - results of 116 treatment courses in 54 patients. Chest 2009; 135: 468-476.
34. Sollberger M, Fluri F, Baumann T, et al: Successful treatment of steroid-refractory neurosarcoidosis with infliximab. J Neurol 2004; 251: 760-761. (Pubitemid 38824027)
35. Sweiss N, Welsch M, Curran J, et al: Tumor necrosis factor inhibition as a novel treatment for refractory sarcoidosis. Arthritis Rheum 2005; 53: 788-791. (Pubitemid 41463847)
36. Sood A, Midha V: Symptomatic sinus bradycardia with infliximab. Indian J Gastroenterol 2004; 23: 118-119.
37. Sote Y, Green S, Maddison P: Complete heart block after infliximab therapy. Rheumatology 2008; 47: 227-228. (Pubitemid 351168243)